bluuebunny/crossref_metadata_2025_split huggingface dataset:
Profile of regional fat and fat-free soft tissue accumulation in male athletes
Authors: Takai Yohei , Nakatani Miyuki , Aoki Toru , Komori Daisuke , Oyamada Kazuyuki , Murata Kensuke , Fujita Eiji , Akamine Takuya , Urita Yoshihisa , Yamamoto Masayoshi , Kanehisa Hiroaki 
Published: March 2020

Abstract
Background
It is unclear whether or not the breakpoint (BP), at which the proportion of each of fat mass (FM) and fat-free soft tissue mass (FFSTM) to body mass (BM) alter, exists in male athletes. We examined the hypothesis that in male athletes, the regional FM and FFSTM-BM relationships have a BP, but the body mass at BP (BMBP) differs among the arms, trunk, and legs.

Methods
By using a dual X-ray absorptiometry, whole-body and regional FMs and FFSTMs in the arms, trunk, and legs were estimated in 198 male athletes (20.8 ± 2.1 years; 1.73 ± 0.07 m; 72.7 ± 14.8 kg). To detect the BP in the relationship between each of FM and FFSTM and BM, a piecewise linear regression analysis was used. If a BP was detected in the corresponding relationship, the significant difference between the regression slopes above and below the BP was examined.

Results
The regression analysis indicated that the BMBP existed in the FM- and FFSTM-BM relationships regardless of region and whole body. For the whole body, BMBP was 81.8 kg for FM and 82.2 kg for FFSTM. In regional FM-BM relationships, BMBP was 80.5 kg for arms, 82.6 kg for trunk, and 63.3 kg for legs, and the regression slopes above the BMBP became higher than those below the BP, and vice versa in regional FFSTM-BM relationships (BMBP 104.6 kg for arms, 80.9 kg for trunk, and 79.0 kg for legs). The relative differences in the slopes between below and above BMBP in the regional FM-BM relationships were higher in the arms and trunk than in the legs, and those in the regional FFSTM-BM relationships in the legs than in the trunk.

Conclusion
Whole-body and regional FM- and FFSTM-BM relationships for male athletes have breakpoints at which the proportion of the tissue masses to BM alters. The BMBP and differences in the distribution of regional FM and FFSTM around the breakpoint are region specific.
Endoscopic cartilage myringoplasty with the removal of a small rim of the external auditory canal to repair marginal perforations
Authors: Lou Zheng-cai 
Published: March 2020

Objective To evaluate the graft success rate and postoperative hearing gain for marginal perforations using endoscopic cartilage myringoplasty with the removal of a small rim of the external auditory canal (EAC). Study design Prospective case series. Materials and methods We performed a prospective study in 41 patients with marginal perforations who underwent endoscopic cartilage myringoplasty with the removal of a small rim of EAC. Patients were followed up for 6 months. Results Of the 41 patients with unilateral marginal perforation included in this study, the graft success rate was 100% (41/41). The mean ABG improved from 11.31 ± 9.71 dB preoperatively to 7.31 ± 2.32 dB postoperatively for small-and medium-sized perforations ( P = 0.13); the mean ABG improved from 21.46 ± 8.39 dB preoperatively to 9.84 ± 2.41 dB postoperatively for large perforations ( P < 0.05); the mean ABG improved from 28.79 ± 6.74 dB preoperatively to 10.13 ± 3.56 dB postoperatively for subtotal and total perforations ( P < 0.05). There were no cases of graft lateralization or significant blunting or atelectasis or graft adhesions. Three patients developed postoperative otorrhoea and five patients had mild myringitis. Conclusions Endoscopic cartilage myringoplasty with the removal of a small rim of the EAC is simple and feasible, showing a high graft success rate and minimal complications for repairing marginal perforations.
Essential in-vitro laboratory diagnostic services provision in accordance with the WHO standards in Guragae zone primary health care unit level, South Ethiopia
Authors: Shumbej Teha , Menu Sofia , Gebru Teklemichael , Girum Tadele , Bekele Fitsum , Solomon Absra , Mesfin Dereje , Jemal Abdulewhab 
Published: March 2020

AbstractIntroductionLaboratory services are crucial parts of the health system having a great contribution to disease prevention and management. The importance of accurate and reliable laboratory test results is less recognized in developing countries like Ethiopia where most medical decisions are based on clinical judgment. It is time for countries like Ethiopia to not only increase health care coverage but also improve access to essential diagnostic tests. Hence, this proposed study aims to assess essential in-vitro laboratory service provision in accordance with the WHO standards in Guragae Zone primary health care unit level, South Ethiopia.MethodsHealth institution-based cross-sectional study was carried out. 30% randomly selected primary health care units were recruited. Each facility was visited with a WHO checklist by a trained data collector to assess the availability of essential diagnostics service provision. The proportion of available in-vitro diagnostics services was calculated. Results were presented as percentages in tables and figures.ResultTwenty-one primary health care facilities located in Guragae Zone were assessed between May and July 2019. All surveyed facilities had major gaps in essential test availability. Among essential diagnostic tests listed with WHO like C-reactive protein, lipid profile, Amylase and Lipase, TroponinT/I, hepatitis B e-antigen, IgM-specific antibodies to hepatitis B core antigen, Glucose-6-phosphate dehydrogenase activity, and anti-HIV/p24 rapid test were not provided in any facilities. However, essential diagnostic services like urine dipstick testing, random blood sugar, smear microscopy, and few serological tests were provided at all primary health care units. All surveyed facilities had limited major laboratory equipment and consumables.Conclusion and recommendationThe present study shows limited access to essential laboratory tests at the primary health care level. Hence, the responsible body should invest to make essential tests accessible at the primary care unit level within the framework of universal health coverage in the study area. The fact that access to essential diagnostic tests is the first key step in improving quality of care; such study has its own efforts to enable the implementation of essential diagnostic lists, and improve access to diagnostics in the country.
Associations between low muscle mass, blood-borne nutritional status and mental health in older patients
Authors: Gariballa Salah , Alessa Awad 
Published: March 2020

Abstract
Background
Although low muscle mass is an important predictor of increased physical morbidity in older patients, information on its impact on mental health and well-being is lacking. The first aim of this report is to look for associations if any between low muscle mass and mental health of older people in clinical practice. The second aim is to study underlying mechanisms including nutritional status.

Methods
In this prospective longitudinal study we randomly selected and studied 432 hospitalized older patients’ baseline demographic data, clinical characteristics and nutritional status on admission, at 6 weeks and at 6 months. Low muscle mass was diagnosed using anthropometric measures based on the European Working Group criteria. Mental health outcome measures including cognitive state, depression symptoms and quality of life were also measured.

Results
Out of 432 patients assessed 44 (10%) were diagnosed with low muscle mass. Patients diagnosed with low muscle mass at admission and over a 6-month follow up period had significantly poor cognitive function, quality of life and increased depression symptoms compared with those with normal muscle mass. After adjustment for poor prognostic indicators, age, disability, severity of acute illness and low muscle mass were associated with poor cognitive function and quality of life and higher depression symptoms in older patients over a 6 months period (p < 0.05). Although patients with low muscle mass had lower micronutrient concentrations compared to those patients with normal muscle mass, only serum albumin showed significant correlations with quality of life at admission and depression symptoms at 6 weeks.

Conclusion
Low muscle mass is associated with poor blood-borne poor nutritional status and mental health in hospitalized older patients, however, this is partly explained by underlying co morbidity.
Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)
Authors: D'Adamo D. R. , Keohan M. , Schuetze S. , Undevia S. , Livingston M. , Cooney M. , Kraft A. , Saulle M. , Schwartz G. K. , Maki R. G. ,   CTEP Sorafenib for Sarcoma Group
Published: March 2020

10001 Background: Sorafenib, an oral multi-targeted tyrosine kinase inhibitor, approved for the treatment of renal carcinoma, inhibits tumor cell proliferation and angiogenesis. We performed a multi-institutional phase II trial of sorafenib in sarcoma. Methods: Six different histological categories were examined, each as a separate Simon two-stage trial. The starting dose of sorafenib was 400 mg PO BID. If â‰¥1 RECIST partial response (PR) was observed in the first 12 pts, 25 more were accrued to that arm. Results: 120 pts (40 M, 80 F) received 553 28-day cycles of therapy as of 1/07. Two RECIST PR were observed in 37 (6%) leiomyosarcoma (LMS) pts and at least 3 PR in 23 (13%) angiosarcomas (AS) pts. No PR were seen in pts with MFH, synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST) or other sarcomas. Median time to progression (mTTP) is 10 (Â ± 2), 15 (Â ± 3), and 23 (Â ± 4) weeks for non-AS, LMS and AS pts, respectively (Kaplan-Meier estimate, Â ± SE). mTTP for AS is >2 fold longer than for other histologies (p=0.039, log rank), and compares favorably with single institution mTTP data for angiosarcoma (paclitaxel 17.3 wk, doxorubicin 16 wk, Fury et al. Cancer J. 2005; 11:241). 64/120 (53%) pts required dose reductions, mostly for dermatological toxicity (see abstract by Keohan, this meeting). Other grade 3, 4 and 5 toxicities included asthenia, hypertension, cardiomyopathy and hemorrhage. Two fatalities, from hemorrhage and intestinal perforation, were deemed possibly related to treatment. Correlative sorafenib pharmacokinetics, MAPK pathway activation and soluble markers of angiogenesis will be presented. Conclusions: Sorafenib has significant activity against angiosarcoma, although the RECIST response rate is low. Sorafenib is associated with disease control in other sarcoma subtypes (e.g. LMS). Accrual continues in AS and MPNST. Further study of sorafenib in sarcomas appears warranted, either in combination with cytotoxic chemotherapy or in a randomized setting. Supported in part by P01-CA47179 Sarcoma Program Project grant and N01 phase II grant. [Table: see text]
Identification of biologically active cancer cells in blood and bone marrow of cancer patients
Authors: Panabières C. , Vendrell J. , Pellé O. , Rebillard X. , Riethdorf S. , Müller V. , Fabbro M. , Pantel K. 
Published: March 2020

1001 Background: Metastasis is the main cause of cancer-related death. Single disseminated tumor cells (DTC) can be detected by sensitive immunocytochemical and molecular technologies, but it is still unclear whether these cells are viable and biologically active. Methods: We applied a novel enzyme-linked immunospot assay (‘EPISPOT‘) that reveals a fingerprint of specific proteins secreted from single viable epithelial tumor cells. The membrane of ELISPOT plates were coated with monoclonal antibodies against the tumor-associated marker proteins mucin-1 (MUC1) for breast cancer and prostate-specific antigen (PSA) for prostate cancer. In addition, dual fluorescent EPISPOT assays were developed to characterize MUC1+ and PSA+ cells (i.e. CK19, FGF2 secretion). Results: Even in the absence of overt metastases (stage M0), the EPISPOT assay revealed viable tumor cells in the peripheral blood of 65% of prostate cancer patients (n=31) and the bone marrow of 54% of breast cancer patients (n=37). Respective samples from non-carcinoma controls were EPISPOT- negative, whereas 80 to 100% of samples from metastatic patients (stage M1, n=40) were positive. The number of EPISPOT-positive cells in M0-patients ranged from 2 to 197 in the blood of prostate cancer patients and 1 to 262 in the bone marrow of breast cancer patients, while M1- patients showed significantly higher counts (prostate cancer, 1–684; breast cancer, 4–813). Interestingly, subsets of MUC1- or PSA-secreting cells expressed a breast stem cell-like phenotype (MUC1-/CK19+) or secreted FGF-2 as factor relevant for the growth of DTC, respectively. Conclusions: A significant fraction of cancer patients harbor viable and biologically active tumor cells in their blood and bone marrow, even in the absence of overt metastases. The multiparameter EPISPOT assay helps to identify these putative metastatic precursor cells. No significant financial relationships to disclose.
Evaluation of local control in patients with non-metastatic Ewing sarcoma of the bone: A report from the Children's Oncology Group
Authors: DuBois S. G. , Krailo M. D. , Cook E. F. , Tarbell N. J. , Fryer C. J. , Gebhardt M. C. , Brown K. , Miser J. S. , Marina N. M. , Grier H. E. 
Published: March 2020

10013 Background: Options for local control in patients (pts) with Ewing sarcoma (EWS) include surgery (S), radiation (R), or surgery plus radiation (S+R). The choice of local control depends on factors that also impact outcome in EWS, including tumor site, tumor size, and age. Our objective was to determine if risk of disease progression differs between local control methods, after controlling for potential confounders. Methods: We analyzed the cohort of pts with non-metastatic EWS of the bone treated on Intergroup Study-0091 (Grier et al, NEJM, 2003). Local control decisions were made on an individual basis. We excluded pts with tumors of the skull/face, progression prior to end of local control, or incomplete local control data. Disease progression was recorded from end of local control. Cumulative incidence of disease progression was determined using a competing risks approach. We constructed a Cox proportional hazards model of progression free survival incorporating local control mode and potential confounders into the model. Secondary analyses evaluated overall survival, local failure, and distant failure. Results: 329 pts met eligibility criteria for analysis. 122 pts received S, 142 received R, and 65 received S+R. The cumulative incidence of disease progression at 5 years was 22.1% (95% CI 15.1–29.9%) for S, 36.9% (29.0–44.9%) for R, and 48.1% (35.5- 59.7%) for S+R. Using R as the reference group and controlling for age, tumor size, tumor location, and chemotherapy regimen, the hazard ratio for progression was 0.66 (95% CI 0.38–1.13) for S and 1.55 (0.96–2.49) for S+R. The hazard ratio for death was 0.77 (95% CI 0.44–1.34) for S and 1.46 (0.88–2.42) for S+R. The hazard ratio for local failure was 0.38 (95% CI 0.15–0.98; p=0.04) for S and 0.77 (0.34–1.75) for S+R. The hazard ratio for distant failure was 0.78 (0.42–1.46) for S and 1.60 (0.91–2.82) for S+R. Conclusions: Observed differences in outcome between local control groups are largely due to confounding factors that affect outcome and local control choice. Risk of disease progression, distant failure, or death does not differ between pts who receive S or R. Pts who receive S have a decreased risk of local failure compared to pts who receive R. No significant financial relationships to disclose.
Interruption of imatinib (IM) in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival
Authors: Rios M. , Lecesne A. , Bui B. , Adenis A. , Bertucci F. , Duffaud F. , Emile J. , Chabaud S. , Perol D. , Blay J. ,   French Sarcoma Group
Published: March 2020

10016 Background: IM the first-line treatment for advanced GIST, must be given continuously until disease progression (PD) or intolerance (Blay et al, ASCO 2004). The impact on long term overall survival (OS) of IM discontinuation in responding patients (pts) and its re-introduction at progression is unknown. Methods: This prospective multicenter BFR14 study was initiated in June 2002. After 1 year of IM 400mg/day, 58 pts free from progression were randomly offered to continue or interrupt IM until PD. Pts allocated to the interruption (I) arm could restart IM (same dose) in case of PD. Primary endpoint was progression-free survival (PFS); secondary endpoints were OS, secondary response after IM re-introduction, identification of molecular determinants of response. Survival data were compared using the log-rank test. Results: Pt characteristics were well balanced between the two arms. Current median follow- up after randomization is 37 months (range 0–42): 29/32 pts (91%) in arm I vs. 16/26 pts (62%) in continuous (C) arm experienced PD. IM interruption was significantly associated with reduced PFS (p<10-4) with a median of 6 months (95% CI, 3.5–9.5) for arm I. Among the 26 pts of I arm who restarted IM after first progression, 24 (92%) achieved tumor control (OR or SD), one progressed, one died from an unrelated cause. The 2-yr OS rates were 87% and 92% for arms I and C, respectively (P = 0.78). Conclusions: Despite a significant increase of PD in the experimental arm, IM re-introduction is safe and allows a tumor control in the majority of pts. No unfavourable impact of IM interruption on OS was reported. Treatment interruption could be a therapeutic option in advanced GIST pts exhibiting intolerance to IM. Updated results including mutational analysis will be presented at the meeting. No significant financial relationships to disclose.
Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. A phase II study
Authors: Bui B. N. , Blay J. , Duffaud F. , Hermine O. , Hermine O. , Le Cesne A. 
Published: March 2020

10025 Background: Masitinib mesylate (MM; AB1010) is a protein tyrosine kinase inhibitor (tki) which, in vitro, has greater activity and selectivity than imatinib mesylate (IM) against the wild-type c-Kit receptor and the mutated form in the juxtamembrane region. MM also inhibits the PDGF and FGFR3 receptors. A phase I trial has shown MM safety and tolerability in patients (pts) with different tumor types. One pathological complete response was observed in a pt intolerant to IM. This evidence led to a multicenter phase II trial in non pretreated GIST pts. Methods: Twenty-six pts with advanced or metastatic GIST tumors naive to IM treatment were recruited by the end of October 2006. MM was given orally at the dose of 7.5 mg/Kg/d. Results: Preliminary results are available from 21/26 pts enrolled so far. There were 13 male, 8 female) with a median age of 61 years (range 33–81). The mean tumor size was 104 mm (29- 254), primary tumor origin was in the stomach in 8 cases and small intestine in 9 cases. At pathological review one patient was found to have a low grade stromal uterine sarcoma. After a median follow up of 9 months (4–15), 11/21 (52.4%) patients achieved a partial response, 8(38.1%) are in stable disease; 2 (9.5%) were considered in progression. Three PR were observed in patients with a primary in the lower GI tract and 7 in patients with gastric primary GIST. The low grade uterine sarcoma also showed PR. The progression occurred after 8 weeks in a pt with primary gastric origin, who failed also IM treatment afterwards. The most frequent AEs related to the study drug were Asthenia (observed in 15% of patients), Periorbital oedema, Muscle spasm, Nausea (40% each), Abdominal pain (35%), Rash, Abdominal pain upper, Diarrhea (30 % each) and Vomiting (25 %). Two patients stopped treatment at 87 and 189 days due to skin toxicity G3. Conclusions: These preliminary results, obtained in a small homogeneous population of patients with GIST naïve to IM treatment, show high efficacy of MM and warrant further trials to confirm the efficacy and complete the safety evaluation of this promising TKI. Definitive results and analysis of KIT/PRGFR mutational status will be presented during meeting. No significant financial relationships to disclose.
Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043
Authors: Sleijfer S. , Papai Z. , Le Cesne A. , Scurr M. , Ray-Coquard I. , Collin F. , Pandite L. , Marreaud S. , De Brauwer A. , Blay J. 
Published: March 2020

10031 Background: Currently, there is no standard treatment for pts with advanced STS who relapse after or during standard chemotherapy. Since VEGF is involved in the pathogenesis of STS subtypes, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGF- receptors 1–3, PDGFR-a and β, and c-kit was explored. Methods: Pts had intermediate or high grade advanced or metastatic STS, were ineligible for chemotherapy or had received no more than one combination or 2 single cytotoxic agents for advanced disease. Pts had WHO performance 0–1 and adequate organ function. Progressive disease had to be documented within the last 6 months. Treatment was oral pazopanib at 800 mg daily. Primary end point was progression-free survival at 12 weeks. Secondary end points included response, safety, and overall survival. 4 different strata were studied: leiomyosarcomas, adipocytic STS, synovial sarcomas, and other types of STS. Simon 2-stage design was applied (P1: 40%; P0: 20%; a=β=0.1). Results: As of 11 October, 2006, 111 pts were enrolled. 98.2% had received prior chemotherapy. In 44 pts with validated data no grade 3–4 hematological toxicities were seen, grade 3–4 bilirubin and creatinine elevations in 2 and 1 pts, respectively. Other toxicities (all grades; grade 3–4) were fatigue (53.6%; 9.7%), hypertension (31.7%; 9.7%), and diarrhea (29.3%; 4.8%). Of 80 pts included in the 1st stages of all 4 strata together, 27 were alive and progression-free at 12 weeks. The 2nd stage was opened for further accrual in 3 strata. Complete accrual is anticipated in February 2007. Conclusions: In relapsed or refractory advanced STS, pazopanib has acceptable toxicity. These preliminary results justify further investigation of pazopanib in STS. No significant financial relationships to disclose.